These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2320 related items for PubMed ID: 28640322

  • 1. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI, Bunz TJ, Turpie AGG.
    Thromb Haemost; 2017 Oct 05; 117(10):1841-1847. PubMed ID: 28640322
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
    Coleman CI, Turpie AGG, Bunz TJ, Baker WL, Beyer-Westendorf J.
    Thromb Res; 2018 Mar 05; 163():132-137. PubMed ID: 29407625
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism.
    Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J.
    Am J Med; 2018 Aug 05; 131(8):933-938.e1. PubMed ID: 29526541
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
    Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J.
    J Thromb Thrombolysis; 2018 Oct 05; 46(3):339-345. PubMed ID: 29881958
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB, Skjøth F, Kjældgaard JN, Lip GYH, Nielsen PB, Søgaard M.
    Lancet Haematol; 2017 May 05; 4(5):e237-e244. PubMed ID: 28411120
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
    Costa OS, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore KT, Bunz TJ, Coleman CI.
    J Thromb Thrombolysis; 2021 Feb 05; 51(2):349-358. PubMed ID: 32588288
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A, Desai A, Calixte R, Aparnath M, Hindenburg A, Salzman S, Mathew JP.
    Lung; 2016 Aug 05; 194(4):605-11. PubMed ID: 27192990
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ, San Agustin K, DeAngelo J, Campbell AM.
    Ann Pharmacother; 2020 Apr 05; 54(4):344-350. PubMed ID: 31672028
    [Abstract] [Full Text] [Related]

  • 12. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
    Coleman CI, Baugh C, Crivera C, Milentijevic D, Wang SW, Lu L, Nelson WW.
    J Med Econ; 2017 Feb 05; 20(2):200-203. PubMed ID: 27780397
    [Abstract] [Full Text] [Related]

  • 13. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
    Spyropoulos AC, Ashton V, Chen YW, Wu B, Peterson ED.
    Thromb Res; 2019 Oct 05; 182():159-166. PubMed ID: 31493618
    [Abstract] [Full Text] [Related]

  • 14. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
    Okumura Y, Fukuda I, Nakamura M, Yamada N, Takayama M, Maeda H, Yamashita T, Ikeda T, Mo M, Yamazaki T, Hirayama A, J’xactly Investigators.
    BMJ Open; 2018 Jun 22; 8(6):e020286. PubMed ID: 29934383
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK, Dietrich E, Smith SM, Davis K, Park H.
    Clin Ther; 2020 Sep 22; 42(9):e161-e176. PubMed ID: 32768247
    [Abstract] [Full Text] [Related]

  • 17. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
    Fung KP, Chan KH, Ng V, Tsui PT, You JHS.
    Cardiovasc Drugs Ther; 2019 Jun 22; 33(3):331-337. PubMed ID: 30888571
    [Abstract] [Full Text] [Related]

  • 18. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L, Sanchez-Oro-Gomez R, Elias-Hernandez T, Morillo-Guerrero R, Ferrer-Galvan M, Asensio-Cruz MI, Barrot-Cortes E, Otero-Candelera R.
    Thromb Res; 2014 Sep 22; 134(3):617-21. PubMed ID: 25034320
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM, Silva MA, Donovan JL, Kanaan AO.
    Clin Ther; 2014 Oct 01; 36(10):1454-64.e3. PubMed ID: 25092394
    [Abstract] [Full Text] [Related]

  • 20. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
    Lee JH, Hyun DG, Choi CM, Lee JC, Kim WS, Oh YM, Lee SD, Lee JS.
    Respiration; 2019 Oct 01; 98(3):203-211. PubMed ID: 31096241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 116.